CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: To characterize the multimodal heterogeneity within the Lin-CD34+ and Lin-CD34+CD38-/low CML bone marrow (BM) compartment at diagnosis and estimate how the heterogeneity contributes to therapy response, we applied CITE-seq on nine patients retrospectively stratified according to molecular response following 12 months of treatment.